OTCMKTS:TRLPF Acerus Pharmaceuticals (TRLPF) Stock Price, News & Analysis $0.22 0.00 (0.00%) As of 07/21/2023 Add Compare Share Share Stock Analysis Stock Analysis About Acerus Pharmaceuticals Stock (OTCMKTS:TRLPF) Get Acerus Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.22▼$0.2250-Day Range$0.22▼$0.2252-Week Range$0.08▼$0.34VolumeN/AAverage Volume5,474 shsMarket Capitalization$56.90 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Acerus Pharmaceuticals Corporation was a Canadian specialty pharmaceutical company focused on developing and commercializing products in men’s health and other therapeutic areas. The company’s operations centered on prescription medicines designed to address unmet needs in hormone replacement therapy and related fields. Acerus’ principal product was Natesto, a testosterone nasal gel used as testosterone replacement therapy for men with conditions associated with low testosterone. The product was developed as an alternative to injectable, topical and implantable testosterone treatments and was marketed in Canada and the United States through commercialization and licensing arrangements. The company was formerly known as Trimel Pharmaceuticals Corporation and adopted the Acerus name as it expanded its focus on commercial-stage specialty pharmaceuticals. Acerus later encountered financial difficulties and pursued restructuring proceedings, and publicly available information about its current operations, leadership and product commercialization activities is limited.AI Generated. May Contain Errors. Read More Receive TRLPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TRLPF Stock News HeadlinesTakeda Pharmaceutical Co. Ltd. ADRFebruary 8, 2024 | wsj.com2023 A Big Year For Testosterone: AbbVie And ANI Pharmaceuticals Best Positioned To BenefitJanuary 1, 2023 | seekingalpha.comThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.October 5 at 1:00 AM | Reagan Gold Group (Ad)Acerus Reports Second Quarter 2022 Financial ResultsAugust 9, 2022 | financialpost.comFAcerus Reports Fourth Quarter and Full Year 2021 Financial ResultsMarch 15, 2022 | financialpost.comFSee More Headlines TRLPF Stock Analysis - Frequently Asked Questions How have TRLPF shares performed this year? Acerus Pharmaceuticals' stock was trading at $0.22 at the beginning of the year. Since then, TRLPF stock has increased by 0.0% and is now trading at $0.22. How were Acerus Pharmaceuticals' earnings last quarter? Acerus Pharmaceuticals Co. (OTCMKTS:TRLPF) released its quarterly earnings results on Monday, November, 5th. The specialty pharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.01). The specialty pharmaceutical company earned $1.58 million during the quarter. Acerus Pharmaceuticals had a negative net margin of 254.66% and a negative trailing twelve-month return on equity of 346.72%. How do I buy shares of Acerus Pharmaceuticals? Shares of TRLPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/05/2018Today10/05/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:TRLPF CIKN/A Webwww.aceruspharma.com Phone416-679-0771FaxN/AEmployees29Year Founded2008Profitability EPS (Trailing Twelve Months)($0.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.79 million Net Margins-254.66% Pretax MarginN/A Return on Equity-346.72% Return on Assets-94.54% Debt Debt-to-Equity Ratio0.64 Current Ratio1.35 Quick Ratio0.90 Sales & Book Value Annual Sales$7.38 million Price / Sales7.71 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares258,615,000Free FloatN/AMarket Cap$56.90 million OptionableNot Optionable Beta2.60 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (OTCMKTS:TRLPF) was last updated on 10/5/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acerus Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acerus Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TRLPF Stock Alerts